Skip to main content
AAO-HNSF 2025 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Scientific Oral Presentations

Rhinology/Allergy

Session: Scientific Oral Presentations 2 - Rhinology/Allergy

Impact of Immunosuppressive Medications on CRS and ESS in Kidney and Liver Transplant Recipients

Sunday, October 12, 2025
1:36 PM - 1:42 PM EDT
Location: 125
Disclosure(s):
Hannah A. Daniel, MD, MBA:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Bastien A. Valencia, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Prishae M. Wilson, BS:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Angela M. Donaldson, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Introduction: Transplant recipients have a higher prevalence of chronic rhinosinusitis (CRS) than the general population, potentially due to immunosuppressive medications. To date, the association between immunosuppressive regimens and CRS development remains unexplored. This study examines the impact of immunosuppressive regimens on CRS development in kidney and liver transplant recipients.

Methods: Data were retrospectively collected from all Mayo Clinic sites using the Mayo Data Explorer. Patients who underwent kidney or liver transplantation between November 1, 2021, and November 1, 2022, were included. Demographic data, relevant comorbidities, CRS diagnoses, and immunosuppressive regimens were collected.

Results: 1,459 transplant recipients (986 kidney, 473 liver) with a mean age of 55.1 years and M:F ratio of 1.5:1 were included. Kidney recipients who received anti-thymocyte globulin (ATG, Thymoglobulin®) for immunosuppressive induction had a higher risk of CRS compared to those who did not (OR = 3.0, 95% CI [1.3, 6.9], p = 0.005). Among liver recipients, patients on cyclosporine, mycophenolate mofetil (MMF), and corticosteroids had a higher risk of CRS compared to those on tacrolimus-based regimens (OR = 6.0, 95% CI [1.5, 24.1], p = 0.027). Cyclosporine use was also associated with a higher rate of ESS compared to tacrolimus (4.2% vs 0.3%, p = 0.015).

Conclusions: ATG and cyclosporine-based regimens are associated with an increased risk of CRS following kidney and liver transplantation. Cyclosporine use is also associated with higher rates of surgical intervention (ESS) for symptom control. These findings may inform patient counseling and guide surgical decision-making in this population.

    Presenting Author(s)

  • HD

    Hannah A. Daniel, MD, MBA

    Resident
    Mayo Clinic Florida
    Jacksonville, FL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • HD

    Hannah A. Daniel, MD, MBA

    Resident
    Mayo Clinic Florida
    Jacksonville, FL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Co-Author(s)

  • Bastien A. Valencia, MD

    Postdoctoral Research Fellow
    Mayo Clinic
    Jacksonville, Florida, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • Bastien A. Valencia, MD

    Postdoctoral Research Fellow
    Mayo Clinic
    Jacksonville, Florida, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • Prishae M. Wilson, BS

    Research Fellow
    Mayo Clinic
    Atlanta, Georgia, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • Prishae M. Wilson, BS

    Research Fellow
    Mayo Clinic
    Atlanta, Georgia, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • NN

    Natasha Najmi, BS

    Mayo Clinic in Florida, United States

    Disclosure information not submitted.

  • NN

    Natasha Najmi, BS

    Mayo Clinic in Florida, United States

    Disclosure information not submitted.

  • HW

    Hani M. Wadei, MD

    Professor of Medicine
    Mayo Clinic in Florida
    Jacksonville, FL, United States

    Disclosure information not submitted.

  • HW

    Hani M. Wadei, MD

    Professor of Medicine
    Mayo Clinic in Florida
    Jacksonville, FL, United States

    Disclosure information not submitted.

  • DH

    Denise Harnois, DO

    Mayo Clinic in Florida, United States

    Disclosure information not submitted.

  • DH

    Denise Harnois, DO

    Mayo Clinic in Florida, United States

    Disclosure information not submitted.

    • Senior Author(s)

  • AD

    Angela M. Donaldson, MD

    Associate Professor
    Mayo Clinic
    Jacksonville, FL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • AD

    Angela M. Donaldson, MD

    Associate Professor
    Mayo Clinic
    Jacksonville, FL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.